Administrative patent review procedures are an effective way of correcting erroneously granted biologic patents and may help promote timely drug competition for the benefit of patients and the US healthcare system.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
RAND Corporation. Biosimilar drugs could generate $38.4 billion in savings over five years. https://www.rand.org/news/press/2022/01/10.html (10 January 2022).
Committee on Oversight and Reform, US House of Representatives. Drug Pricing Investigation: Majority Staff Report https://oversightdemocrats.house.gov/sites/democrats.oversight.house.gov/files/DRUG%20PRICING%20REPORT%20WITH%20APPENDIX%20v3.pdf (2021).
Goode, R. & Chao, B. H. J. Law Biosci. 9, 1–24 (2022).
Rai, A. K. et al. Berkeley Technol. Law J. 37, 101–130 (2022).
Van de Wiele, V. L., Kesselheim, A. S. & Sarpatwari, A. Health Aff. (Millwood) 40, 1198–1205 (2021).
Van de Wiele, V. L., Beall, R. F., Kesselheim, A. S. & Sarpatwari, A. Nat. Biotechnol. 40, 22–25 (2022).
Leahy–Smith America Invents Act. Public Law 112-29, 112th Congress. https://www.uspto.gov/sites/default/files/aia_implementation/20110916-pub-l112-29.pdf (2011).
Phillips v. AWH Corp. 415 F.3d 1303 (Fed. Cir. 2005).
Darrow, J. J., Beall, R. F. & Kesselheim, A. S. Nat. Biotechnol. 35, 1139–1141 (2017).
Darrow, J. J., Sarpatwari, A. & Curfman, G. Yale J. Health Policy Law Ethics 19, 250–256 (2019).
Rai, A. K. et al. Berkeley Technol. Law J. 37, 139–169 (2022).
Hovenkamp, E., Lemus, J., Rai, A. & Vishnubhakat, S. Nat. Biotechnol. 40, 1569–1572 (2022).
US Patent & Trademark Office. PTAB Orange Book Patent/Biologic Patent Study FY21 Q3 https://www.uspto.gov/sites/default/files/documents/PTABOBbiologicpatentstudy8.10.2021draftupdatedthruJune2021.pdf (2021).
Tu, S. S. & Lemley, M. A. Wash. Univ. Law Rev. 99, 1673–1731 (2022).
Duan, C. Am. Univ. Law Rev. 72, 1133–1178 (2023).
Acknowledgements
National Institutes of Health Care Management (NIHCM). A.S.K. and S.S.T. also receive support from Arnold Ventures and the Commonwealth Fund. The funders had no role in the preparation, review or approval of the manuscript or the decision to submit the manuscript for publication.
Author information
Authors and Affiliations
Corresponding author
Supplementary information
Supplementary Information
Supplementary Fig. 1 and Tables 1–4
Rights and permissions
About this article
Cite this article
Van de Wiele, V.L., Kesselheim, A.S. & Tu, S.S. Biologic patent challenges under the America Invents Act. Nat Biotechnol 42, 374–377 (2024). https://doi.org/10.1038/s41587-024-02156-9
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-024-02156-9